Grigg AP - Search Results

1

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.

Harrison CN, Campbell PJ, Buck G, Wheatley K, East CL, Bareford D, Wilkins BS, van der Walt JD, Reilly JT, Grigg AP, Revell P, Woodcock BE, Green AR; United Kingdom Medical Research Council Primary Thrombocythemia 1 Study. Harrison CN, et al. Among authors: grigg ap. N Engl J Med. 2005 Jul 7;353(1):33-45. doi: 10.1056/NEJMoa043800. N Engl J Med. 2005. PMID: 16000354 Free article. Clinical Trial.

2

Long-term interferon-alpha 2A does not induce sustained hematologic remission in younger patients with essential thrombocythemia.

Bentley M, Taylor K, Grigg A, Kronenberg H, Gibson J, Bunce I, Eliadis P, Olsen T, Wright S, Taylor D, Rodwell R. Bentley M, et al. Leuk Lymphoma. 1999 Dec;36(1-2):123-8. doi: 10.3109/10428199909145955. Leuk Lymphoma. 1999. PMID: 10613456

3

Multiple cycles of aggressive chemotherapy prior to autologous peripheral stem cell transplantation for lymphoma.

Goss G, Szer J, Basser R, Fox R, Grigg A. Goss G, et al. Aust N Z J Med. 1997 Jun;27(3):323-9. doi: 10.1111/j.1445-5994.1997.tb01986.x. Aust N Z J Med. 1997. PMID: 9227818 Clinical Trial.

4

Effect of hydroxyurea on sperm count, motility and morphology in adult men with sickle cell or myeloproliferative disease.

Grigg A. Grigg A. Intern Med J. 2007 Mar;37(3):190-2. doi: 10.1111/j.1445-5994.2006.01290.x. Intern Med J. 2007. PMID: 17316339

5

Phase II study of autologous filgrastim (G-CSF)-mobilized peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies.

Sheridan WP, Begley CG, To LB, Grigg A, Szer J, Maher D, Green MD, Rowlings PA, McGrath KM, Cebon J, et al. Sheridan WP, et al. Bone Marrow Transplant. 1994 Jul;14(1):105-11. Bone Marrow Transplant. 1994. PMID: 7524904 Clinical Trial.

6

Intermediate dose cyclophosphamide combined with a growth factor is a safe and effective regimen for mobilisation of peripheral blood progenitor cells.

Goss G, Szer J, Grigg A. Goss G, et al. Aust N Z J Med. 1996 Jun;26(3):411-3. doi: 10.1111/j.1445-5994.1996.tb01931.x. Aust N Z J Med. 1996. PMID: 8811217 Clinical Trial. No abstract available.

7

G-CSF stimulated donor granulocyte collections for prophylaxis and therapy of neutropenic sepsis.

Grigg A, Vecchi L, Bardy P, Szer J. Grigg A, et al. Aust N Z J Med. 1996 Dec;26(6):813-8. doi: 10.1111/j.1445-5994.1996.tb00630.x. Aust N Z J Med. 1996. PMID: 9028513

8

Factors influencing the outcome of donor marrow transplantation in adults from less than ideal donors: experience from two Australian centres.

Grigg A, Morton J, Durrant S, Bardy P, Szer J. Grigg A, et al. Aust N Z J Med. 1997 Jun;27(3):311-8. doi: 10.1111/j.1445-5994.1997.tb01984.x. Aust N Z J Med. 1997. PMID: 9227816

9

The tyrosine kinase inhibitor, nilotinib potentiates a prothrombotic state.

Alhawiti N, Burbury KL, Kwa FA, O'Malley CJ, Shuttleworth P, Alzard M, Hamadi A, Grigg AP, Jackson DE. Alhawiti N, et al. Among authors: grigg ap. Thromb Res. 2016 Sep;145:54-64. doi: 10.1016/j.thromres.2016.07.019. Epub 2016 Jul 30. Thromb Res. 2016. PMID: 27494773

10

New approaches to the management of poor prognosis non-seminomatous germ cell tumours.

Grigg A, McKendrick J, Fox R. Grigg A, et al. Aust N Z J Med. 1992 Dec;22(6):679-84. doi: 10.1111/j.1445-5994.1992.tb04870.x. Aust N Z J Med. 1992. PMID: 1489291 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

203 results

Search Page

Filters